Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.36 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.36 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.36 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.36 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.36 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.36 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.36 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 14/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18965789 | 0.91 | ATP1A1 (0.35) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| SCHEMBL18965941 | 0.90 | CYP3A4 (0.39) | CYP3A4PPARGATP1A1ATP1B1ATP1A3 | |
| SCHEMBL18965935 | 0.89 | SCN9A (0.44) | SCN9AMCHR1 | |
| SCHEMBL17488173 | 0.84 | CYP3A4 (0.48) | CYP3A4PPARGP2RX3 | |
| SCHEMBL18960419 | 0.83 | CYP3A4 (0.43) | CYP3A4PPARGATP1A1ATP1B1ATP1A3 | |
| SCHEMBL17488255 | 0.82 | MCHR1 (0.42) | SCN9AMCHR1 | |
| SCHEMBL18965850 | 0.81 | CYP3A4 (0.41) | CYP3A4PPARGSCN9AP2RX3MCHR1 | |
| SCHEMBL18965860 | 0.81 | CYP3A4 (0.44) | CYP3A4PPARGP2RX3 | |
| SCHEMBL18965852 | 0.80 | CYP3A4 (0.41) | CYP3A4PPARGSCN9AP2RX3HRH3 | |
| SCHEMBL17487963 | 0.80 | CYP3A4 (0.41) | CYP3A4P2RX3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| WO-2016016421-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | CYP3A4 261/4885PPARG 472/4885ATP1A1 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.